More Information: Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.

Alexia Iasonos, PhD

Associate Attending Biostatistician

Alexia Iasonos, Associate Attending Biostatistician

Office Phone




University of Albany

Current Research Interests

Dr. Iasonos has been at MSKCC since early 2005. She has collaborated primarily with investigators studying ovarian cancer and also with investigative teams studying bladder cancer, lymphoma, and health outcomes. Through her collaborations with investigators in gynecology (Departments of Surgery, Medicine and Pathology)  she is exploring various biomarkers and assessing relationships to histology, metastasis and clinical outcome. She is also involved in vaccine trials as a second line therapy in ovarian cancer patients, and in identifying valid endpoints for these trials. Her methodological interests focus on model based designs that guide the dose escalation in phase I trials and in the past few years she has focused on the design of early phase trials that involve dose expansion cohorts.


Selected peer-reviewed publications:

  1. Iasonos A, O’Quigley J. Dose expansion cohorts in Phase I trials. Stat Biopharm Res. 2016;8(2):161-170. Epub 2016 Jun 2. PubMed PMID: 27516848; PubMed Central PMCID: PMC4976787.

  2. Iasonos A, O’Quigley J. Clinical trials: Early phase clinical trials-are dose expansion cohorts needed? Nat Rev Clin Oncol. 2015 Nov;12(11):626-8. doi:10.1038/nrclinonc.2015.174. Epub 2015 Oct 6. PubMed PMID: 26441082; PubMed Central PMCID: PMC4758199.

  3. Satagopan JM, Iasonos A. Measuring differential treatment benefit across marker specific subgroups: The choice of outcome scale. Contemp Clin Trials. 2017 Feb 22. pii: S1551-7144(16)30093-3. doi: 10.1016/j.cct.2017.02.007. [Epub ahead of print] PubMed PMID: 28254404.

  4. Iasonos A, O’Quigley J. Adaptive dose-finding studies: a review of model-guided phase I clinical trials. J Clin Oncol. 2014 Aug 10;32(23):2505-11. doi: 10.1200/JCO.2013.54.6051. Epub 2014 Jun 30. Review. PubMed PMID: 24982451; PubMed Central PMCID: PMC4121508.

  5. Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008 Mar 10;26(8):1364-70. doi: 10.1200/JCO.2007.12.9791. Review.

For a complete list of publications: